bioAffinity Technologies, Inc. - 8-K Filing

bioAffinity Technologies reports Q3 2026 revenue of $1.1M and a net loss of $5.3M despite doubling CyPath Lung unit sales year-to-date. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 6, 2026, 22:28 UTC

Tickers: $BIAF

Read the full article at SEC EDGAR

More Regulatory news

SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
RF Acquisition Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 14:04 UTC
ORASURE TECHNOLOGIES INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Rocket Companies, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Dare Bioscience, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC